NPOP aims to bring individualized cancer treatment based on genomic testing to Veterans across the country. Researchers sequenced DNA from tumors of more than 3,000 Veterans with cancer.

52% had FDA-approved treatment available
9% had experimental targeted therapy available through clinical trials
9% had potential treatment via a drug approved for a different cancer

70% had actionable mutations (meaning precision treatment is available)

30% No current actionable mutations